More powerful two-sample tests for differences in repeated measures of adverse effects in psychiatric trials when only some patients may be at risk.
Common adverse effect measures in psychiatric trials are typically analysed with repeated measures ANOVA, despite having distributions which violate key assumptions of that method; moreover, some adverse effects may be concentrated in vulnerable subgroups of participants. For testing treatment differences in adverse effects, we propose use of Kendall's taub as a summary measure of within-participant trends in adverse events, in conjunction with a weighted modification of a rank test proposed by Conover and Salsburg. Data on extrapyramidal side effects from a controlled clinical trial conducted in persons with treatment resistant schizophrenia was used to compare the proposed analysis to repeated measures ANOVA using mixed models and alternate tests for treatment differences in taub trend scores.
McMahon
Robert P
RP
Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland Baltimore Medical School, Baltimore MD, USA. rmcmahon@mprc.umaryland.edu
Arndt
Stephan
S
Conley
Robert R
RR
D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001480:Basal Ganglia Diseases / Q000139:chemically induced; D001569:Benzodiazepines / Q000009:adverse effects / Q000627:therapeutic use; D002746:Chlorpromazine / Q000009:adverse effects / Q000627:therapeutic use; D003198:Computer Simulation; D003627:Data Interpretation, Statistical; D004311:Double-Blind Method; D006801:Humans; D000077152:Olanzapine; D011570:Psychiatry / Q000379:methods*; D016032:Randomized Controlled Trials as Topic / Q000379:methods*; D012559:Schizophrenia / Q000188:drug therapy*
D014150:Antipsychotic Agents; D001569:Benzodiazepines; D000077152:Olanzapine; D002746:Chlorpromazine